Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics Bill Clears Senate Cmte. With Stronger Language On Exclusivity Cap

This article was originally published in The Pink Sheet Daily

Executive Summary

Generic firms remain concerned that innovators would be able to "evergreen" their products through minor changes.
Advertisement

Related Content

Follow-On Biologics Legislation Could Reach Senate Floor By Year End
Follow-On Biologics Legislation Could Reach Senate Floor By Year End
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Follow-On Biologics Deal Gives Brands 12 Years Of Exclusivity
Follow-On Biologics Deal Gives Brands 12 Years Of Exclusivity
Follow-On Biologics Get Their Vehicle As Senate Schedules Mark-Up For June 13

Topics

Advertisement
UsernamePublicRestriction

Register

PS066243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel